KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBITDA: 2009-2025

Historic EBITDA for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $133.8 million.

  • Charles River Laboratories International's EBITDA rose 13.96% to $133.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.9 million, marking a year-over-year decrease of 73.31%. This contributed to the annual value of $227.3 million for FY2024, which is 63.17% down from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's EBITDA is $133.8 million, which was up 33.62% from $100.1 million recorded in Q2 2025.
  • Charles River Laboratories International's EBITDA's 5-year high stood at $187.4 million during Q2 2022, with a 5-year trough of -$167.7 million in Q4 2024.
  • Over the past 3 years, Charles River Laboratories International's median EBITDA value was $132.9 million (recorded in 2023), while the average stood at $104.8 million.
  • In the last 5 years, Charles River Laboratories International's EBITDA surged by 79.18% in 2021 and then crashed by 226.15% in 2024.
  • Over the past 5 years, Charles River Laboratories International's EBITDA (Quarterly) stood at $172.8 million in 2021, then declined by 5.21% to $163.8 million in 2022, then decreased by 18.86% to $132.9 million in 2023, then plummeted by 226.15% to -$167.7 million in 2024, then rose by 13.96% to $133.8 million in 2025.
  • Its EBITDA was $133.8 million in Q3 2025, compared to $100.1 million in Q2 2025 and $74.7 million in Q1 2025.